PBLA · Panbela Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $6.05M | $7.00M | $5.52M | - | $6.74M | $4.23M | $3.51M | - | $2.33M | $20.03M |
| SG&A | $1.11M | $1.11M | $1.20M | - | $1.11M | $1.64M | $1.35M | - | $1.29M | $1.26M |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($7.17M) | ($8.10M) | ($6.73M) | - | ($7.85M) | ($5.88M) | ($4.86M) | - | ($3.62M) | ($21.29M) |
| Interest Expense | $71.0K | $70.0K | $63.0K | - | $71.0K | $70.0K | $102.0K | - | $87.0K | $16.0K |
| Income Tax | $0 | $0 | ($138.0K) | - | ($19.0K) | ($147.0K) | $0 | - | ($56.0K) | ($18.0K) |
| Net Income | ($7.17M) | ($7.14M) | ($7.12M) | - | ($7.83M) | ($5.83M) | ($5.11M) | - | ($4.40M) | ($22.13M) |
| EPS - Basic | ($1.48) | ($1.47) | ($2.28) | - | ($53.80) | ($159.00) | ($390.00) | - | ($3840.00) | ($36240.00) |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $142.0K | $59.0K | $262.0K | $2.58M | $907.0K | $7.21M | $5.24M | $1.28M | $941.0K | $2.53M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $10.95M | $14.29M | $8.51M | $9.94M | $6.61M | $8.44M | $7.34M | $2.87M | $5.39M | $3.21M |
| Current Assets | $5.17M | $772.0K | $1.78M | $3.06M | $1.89M | $10.81M | $7.83M | $1.78M | $1.77M | $3.46M |
| Total Assets | $5.17M | $9.41M | $10.53M | $11.80M | $10.63M | $19.55M | $16.48M | $4.98M | $4.87M | $6.56M |
| Current Liabilities | $20.14M | $16.79M | $10.52M | $12.32M | $8.92M | $10.55M | $9.75M | $7.83M | $7.95M | $6.20M |
| Long-term Debt | $3.19M | $3.19M | $3.19M | $4.19M | $4.19M | $4.19M | $4.19M | $5.19M | $5.19M | $0 |
| Total Liabilities | $23.34M | $19.98M | $13.71M | $16.51M | $13.11M | $14.75M | $13.94M | $13.03M | $13.15M | $11.39M |
| Stockholders' Equity | ($18.17M) | ($10.57M) | ($3.19M) | ($4.71M) | ($2.48M) | $4.80M | $2.54M | ($8.05M) | ($8.28M) | ($4.84M) |
| Retained Earnings | ($146.94M) | ($139.76M) | ($132.62M) | ($125.50M) | ($109.88M) | ($102.05M) | ($96.21M) | ($91.09M) | ($86.36M) | ($81.96M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($9.39M) | - | - | - | ($9.75M) | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | $7.08M | - | - | - | $13.70M | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -138.8% | -75.8% | -67.6% | - | -73.7% | -29.8% | -31.0% | - | -90.4% | -337.5% |
| Return on equity | 39.5% | 67.6% | 223.5% | - | 315.4% | -121.5% | -201.7% | - | 53.2% | 457.4% |
| Return on invested capital | - | - | -66419.3% | - | -362.3% | -51.6% | -57.1% | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.26 | 0.05 | 0.17 | 0.25 | 0.21 | 1.02 | 0.80 | 0.23 | 0.22 | 0.56 |
| Quick ratio | 0.26 | 0.05 | 0.17 | 0.25 | 0.21 | 1.02 | 0.80 | 0.23 | 0.22 | 0.56 |
| Cash ratio | 0.01 | 0.00 | 0.02 | 0.21 | 0.10 | 0.68 | 0.54 | 0.16 | 0.12 | 0.41 |
| Leverage | ||||||||||
| Debt / Equity | -0.18 | -0.30 | -1.00 | -0.89 | -1.69 | 0.87 | 1.65 | -0.65 | -0.63 | 0.00 |
| Debt / Assets | 0.62 | 0.34 | 0.30 | 0.36 | 0.39 | 0.21 | 0.25 | 1.04 | 1.07 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -100.9x | -115.8x | -106.8x | - | -110.5x | -84.0x | -47.6x | - | -41.6x | -1330.4x |
| Equity multiplier | -0.28 | -0.89 | -3.30 | -2.51 | -4.28 | 4.07 | 6.50 | -0.62 | -0.59 | -1.36 |
| Liabilities / Assets | 4.52 | 2.12 | 1.30 | 1.40 | 1.23 | 0.75 | 0.85 | 2.62 | 2.70 | 1.74 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 8.7% | -37.9% | -38.4% | - | -116.6% | 72.4% | -21.4% | - | -63.9% | -856.2% |
| Net income growth (YoY) | 8.4% | -22.4% | -39.3% | - | -77.9% | 73.6% | -39.5% | - | -105.5% | -912.4% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -631.7% | - | - | 41.5% | 70.0% | - | -61.5% | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Panbela Therapeutics against the 5 most active filers in the same SIC group.